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Abstract
Introduction About two-thirds of the excess familial risk
associated with breast cancer is still unaccounted for and may
be explained by multiple weakly predisposing alleles. A gene
thought to be involved in low-level predisposition to the disease
is ERBB2 (HER2). This gene is involved in cell division,
differentiation, and apoptosis and is frequently amplified in
breast tumours. Its amplification correlates with poor prognosis.
Moreover, the coding polymorphism I655V has previously been
associated with an increased risk of breast cancer.
Methods We aimed to determine if common polymorphisms
(frequency ≥ 5%) in ERBB2 were associated with breast cancer
risk in a white British population. Five single-nucleotide
polymorphisms (SNPs) were selected for study: SNP 1 near the
promoter, SNP 2 in intron 1, SNP 3 in intron 4, SNP 4 in exon
17 (I655V), and SNP 5 in exon 27 (A1170P). We tested their
association with breast cancer in a large case–control study (n
= 2192 cases and 2257 controls).
Results There were no differences in genotype frequencies
between cases and controls for any of the SNPs examined. To
investigate the possibility that a common polymorphism not
included in our study might be involved in breast cancer
predisposition, we also constructed multilocus haplotypes. Our
set of SNPs generated all existing (n = 6) common haplotypes
and no differences were seen in haplotype frequencies between
cases and controls (P = 0.44).
Conclusions In our population, common ERBB2
polymorphisms are not involved in predisposition to breast
cancer.
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Introduction
Breast cancer is the most common cause of cancer in
women in the United Kingdom and is, after lung cancer, the
most common cause of cancer death (Office for National
Statistics). Positive family history is a well-established risk
factor for the disease: the risk to first-degree relatives of a
breast cancer case is about twice the population risk [1].
Most of the excess familial risk associated with breast can-
cer is likely to be genetic in origin [2,3]. However, only
about a third of this risk is accounted for by known genes,
the most important being BRCA1 and BRCA2, while the
remainder might be explained by a combination of weakly
predisposing alleles [2-4]. A gene thought to be involved in
low-level susceptibility to breast cancer is ERBB2 (HER2).
This gene is located on chromosome 17q12–q21, spans
38 kilobases, and comprises 27 coding exons. It is a mem-
ber of the ERBB family, a family of protein tyrosine kinases
involved in cell division, migration, adhesion, differentiation,
and apoptosis and consisting of EGFR (ERBB1), ERBB2,
ERBB3, and ERBB4 [5]. ERBB2 amplification or overex-
pression is seen in about 25% of breast cancers and has
been associated with metastatic phenotype, endocrine
therapy unresponsiveness, and poor prognosis [6]. ERBB2
is polymorphic in the transmembrane region of the protein
at codon 655 (ATC/isoleucine to GTC/valine [I655V]). The
amino acid change could result in increased protein tyro-
sine kinase activity [7]. Several association studies of
I655V and breast cancer risk have yielded conflictingR204df = degree of freedom; LD = linkage disequilibrium.; OR = odds ratio; SNP = single-nucleotide polymorphism.
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R205results. In a study on 700 Han Chinese women, Xie and
colleagues first reported a significantly increased risk for
carriers of the rare allele (odds ratio [OR] = 1.4) [8]. Only
one of seven subsequent studies showed an overall effect
of I655V on breast cancer risk [9-15]. However, of the neg-
ative studies, all but one had limited power to detect a risk
of this magnitude [13]. Three groups did report associa-
tions in specific subgroup analyses in the absence of over-
all effect: Wang-Gohrke and Chang-Claude showed an
association in women with a positive family history of breast
cancer and McKean-Cowdin and colleagues showed an
association with localized breast cancer, whereas Millikan
and colleagues showed an association in women with a
positive family history who were aged 45 years or younger
as well as an increased risk of carcinoma in situ [12,13,15].
I655V has usually been selected for study because of the
possible functional consequences of the amino acid
change in the transmembrane region of the protein. Many
more single-nucleotide polymorphisms (SNPs) in ERBB2
are known but only one negative study has reported on any
of these [10]. A selected set of sequence polymorphisms
can serve as genetic markers to detect association
between a particular region and the disease, whether or not
the markers themselves have a functional effect [16]. It is
therefore not necessary to test each polymorphism individ-
ually. Because most SNPs are correlated with nearby poly-
morphisms, genotypes at unsassayed, risk-related SNPs
will be correlated with one or more assayed SNPs [17]. If
the set of selected markers provides enough information
about the remainder of the common polymorphisms in that
gene, any susceptibility allele within or close to the gene
should be uncovered through the evaluation of the underly-
ing haplotypes [18]. To clarify the role of ERBB2 in the pre-
disposition to breast cancer, we tested the association of
five common polymorphisms (including I655V) with the dis-
ease in a large case–control study of white British women.
We aimed to identify sufficient SNPs to tag all the common
haplotypes across the gene.
Materials and methods
Patients and controls
Cases were drawn from the Anglian Breast Cancer Study,
an ongoing population-based study with cases ascertained
through the East Anglian Cancer Registry [4]. All women
diagnosed with invasive breast cancer under the age of 55
years between 1 January 1991 and 30 June 1996 and who
were alive at the start of the study (prevalent cases) as well
as women under the age of 70 who were diagnosed from
1996 onwards (incident cases) were eligible for inclusion.
We used prevalent and incident cases in order to maximize
sample size; approximately 65% of eligible patients have
enrolled in the study. Women taking part in the study were
asked to provide a 20-ml blood sample for DNA analysis
and to complete a comprehensive epidemiological ques-
tionnaire. We carried out genotyping on a subset consist-
ing of the first 2192 (1438 incident and 754 prevalent)
enrolled cases. Controls (2257) were randomly drawn from
the Norfolk component of the European Prospective Inves-
tigation of Cancer (EPIC) [19]. The ethnic background of
both cases and controls is similar, with over 98% being
white Anglo-Saxon. Ethical approval was obtained from the
Anglia and Oxford Multicentre Research Committee and
informed consent was obtained from each patient.
SNP identification and selection
SNPs with validated frequency data were identified in Jan-
uary 2004 through the dbSNP database http://
www.ncbi.nlm.nih.gov/SNP/. If these data were from a non-
Caucasian population, we confirmed the presence of the
polymorphism in our population by performing denaturing
high-performance liquid chromatography on a set of 48
genomic DNA samples from UK breast cancer patients.
We selected all nonsynonymous coding SNPs (n = 2),
SNPs located in the promoter region (n = 1), and two ran-
domly chosen intronic SNPs [20]. A total of five SNPs were
thus selected for study (Table 1). In order to have good
power to detect small relative risks, we restricted our atten-
tion to SNPs with a frequency of 5% or more.
Genotyping
Genotyping was carried out using Taqman® (Applied Bio-
systems, Warrington, UK) according to the manufacturer's
instructions. Primers and probes were either supplied
directly by Applied Biosystems in case of Assays-by-
Design™ (SNP 1 and SNP 2) and Assays-on-Demand™
(SNP 3) or designed using Primer Express Oligo Design
Software v2.0 (Applied Biosystems) (SNP 4 and SNP 5).
Sequences are available on request. Reactions were car-
ried out at 54°C (SNP 4) or 60°C (SNP 1, SNP 2, SNP 3,
and SNP 5). All assays were carried out in 384-well plates.
Each plate contained 384 samples including 2 negative
controls with no DNA and 12 samples duplicated on a sep-
arate quality-control plate. Plates were read on the ABI
Prism 7900 using the Sequence Detection Software
(Applied Biosystems). Failed genotypes were not repeated.
Statistical methods
The characteristics of cases and controls were explored
with SPSS© v12.0.1 (SPSS Inc, Chicago, IL, USA). For
each SNP, deviation of genotype frequencies in controls
from the Hardy–Weinberg equilibrium was assessed by χ2
test with one degree of freedom (df). Genotype frequen-
cies in cases and controls or within cases stratified by dis-
ease stage (stage I vs stages II–IV) or age group (≤ 45 vs
>45) were compared by χ2 test for heterogeneity (2df).
Genotype-specific risks were estimated as ORs using
standard cross-product ratio. Confidence intervals were
calculated using the variance of the log (OR), which was
estimated by the standard Taylor expansion. Power was
Available online http://breast-cancer-research.com/content/7/2/R204
R206determined using standard statistical methods [21]. We
have over 90% power at the 1% significance level to detect
a dominant allele with a frequency of 0.05, which confers a
relative risk of 1.5, or a dominant allele with a frequency of
0.2 that confers a relative risk of 1.3. Power to detect
recessive alleles at the 1% significance level is more lim-
ited: 59% for an allele with a frequency of 0.2 that confers
a relative risk of 1.5 or 77% for an allele with a frequency of
0.3 that confers a relative risk of 1.4. The LDA program [22]
was used to calculate pairwise linkage disequilibrium (LD)
for each SNP pair in the whole case–control set. The
haplo.score program [23] was used to test for association
between haplotypes and breast cancer risk. Haplo.score
uses a likelihood that depends on estimated haplotype fre-
quencies to test the statistical association between haplo-
types and phenotype. It is based on score statistics, which
provide both global tests and haplotype-specific tests [23].
Results
The median age was 48 years (range 25–54) for prevalent
cases, 52 years (26–55) for incident cases, and 56 years
(25–81) for controls. Incident and prevalent cases were
similar regarding breast cancer stage (P = 0.12) and histo-
logical grade (P = 0.41). Table 2 shows the genotype fre-
quencies in cases and controls as well as genotype-
specific risks for the five SNPs assayed. The genotype fre-
quencies were similar in the prevalent and incident cases
for all polymorphisms (data not shown). None of the geno-
type distributions for the controls differed significantly from
those expected under Hardy–Weinberg equilibrium. There
was no evidence that any of the SNPs is associated with
breast cancer; genotype-specific ORs were all close to
unity with narrow confidence intervals. We also compared
genotype frequencies within cases stratified by disease
stage and age group for SNP 4 (I655V). No differences
were seen (P [stage] = 0.61, P [age group] = 0.33). LD
was strong (D' > 0.7) across pairs involving SNPs 1, 2, 3,
and 5, whereas SNP 4 was in weak LD (D' < 0.3) with all
other polymorphisms except SNP 1 (D' [SNP 1-SNP 4] =
0.98) (Fig. 1). SNPs 3 and 5 were in nearly perfect LD (r2
= 0.92). Of 32 possible haplotypes, only 6 were observed
with a frequency greater than 5% (Table 3). For the whole
case–control set, common haplotypes constituted 98% of
all the observed haplotypes. Two haplotypes (haplotypes 3
and 5) contained the SNP 4 (I655V) minor allele. The glo-
bal test was not significant (P = 0.44), nor were there any
differences between cases and controls for individual hap-
lotypes. Similarly, no differences in haplotype frequencies
were seen within cases stratified by disease stage (P =
0.37) or age group (P = 0.48).
Discussion
Our study is the largest case–control study reported on
ERBB2 genetic variation. To our knowledge, this is also the
Table 1
Single-nucleotide polymorphisms (SNPs) selected for genotyping
SNP name dbSNP id Location Base change
SNP 1 rs4252596 START -657a C>Ab
SNP 2 rs2952155 intron 1 C>T
SNP 3 rs1810132 intron 4 T>C
SNP 4 rs1801200 exon 17 (I655V) A>G
SNP 5 rs1058808 exon 27 (A1170P) G>C
a657 base pairs upstream first translated base. bCommon allele given first.
Figure 1
Pairwise linkage disequilibrium (LD) measures of D' (left bottom half) and r2 (right top half) for the five SNPs
and r2 (right top half) for the five SNPs.
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polymorphisms and looking for involvement of haplotypes
in breast cancer predisposition. We performed a study of
five common SNPs and found no evidence for association
with breast cancer risk. Four of the polymorphisms may be
functional: SNP 1 near the promoter region and SNP 2 in
intron 1 could be involved in regulatory processes whereas
SNP 4 and SNP 5 are nonsynonymous coding SNPs that
could affect tyrosine kinase activity or protein structure [7].
Two association studies have previously reported a positive
association between SNP 4 (I655V) and breast cancer risk
[8,14]. Both genotyped about 700 individuals and showed
a similarly increased risk for carriers of the Val allele (OR =
1.4). We were not able to replicate these findings. We have
over 90% power to detect a risk of this magnitude at the
10-4 level of significance. This suggests that previous posi-
tive findings may have been due to type I statistical errors.
Neither could we replicate findings associating I655V with
low-stage breast cancer or with breast cancer in younger
women [12,13]. Positive results from stratified analyses
should be treated with caution; very large sample sizes are
required to obtain reliable results, the number of possible
analyses that can be undertaken is large, and there is a
strong possibility that one or more tests will be statistically
significant simply by chance [24]. We could not carry out
analyses within cases stratified by family history, because
we only had incomplete family history data [15]. To investi-
gate the possibility that a common polymorphism not
Table 2
Genotype frequencies and genotype-specific risks in 2192 women with breast cancer and 2257 controls
SNP Series Rare-allele 
frequency
Common homozygote 
No. (%)
Heterozygote No. 
(%)
Rare homozygote 
No. (%)
Number genotyped P (2df)
SNP 1 Cases 0.13 1618 (77) 447 (21) 42 (2) 2107
Controls 0.13 1645 (75) 511 (23) 33 (2) 2189 0.13
OR (95% CI) 1 (ref) 0.89 (0.77–1.03) 1.29 (0.82–2.05)
SNP 2 Cases 0.25 1151 (57) 734 (36) 140 (7) 2025
Controls 0.26 1219 (55) 839 (38) 147 (7) 2205 0.48
OR (95% CI) 1 (ref) 0.93 (0.82–1.05) 1.01 (0.79–1.29)
SNP 3 Cases 0.32 962 (47) 855 (42) 219 (11) 2036
Controls 0.32 1022 (46) 956 (43) 230 (11) 2208 0.69
OR (95% CI) 1 (ref) 0.95 (0.84–1.08) 1.01 (0.82–1.24)
SNP 4 Cases 0.25 1128 (57) 748 (37) 113 (6) 1989
Controls 0.25 1230 (57) 791 (37) 134 (6) 2155 0.69
OR (95% CI) 1 (ref) 1.03 (0.91–1.17) 0.92 (0.71–1.20)
SNP 5 Cases 0.33 911 (45) 870 (43) 233 (12) 2014
Controls 0.33 960 (44) 983 (45) 238 (11) 2181 0.45
OR (95% CI) 1 (ref) 0.93 (0.82–1.06) 1.03 (0.84–1.26)
OR, odds ratio; SNP, single-nucleotide polymorphism.
Table 3
Estimated haplotype frequencies in cases and controls
Haplotype Allelea Frequency (cases) Frequency (controls) Pb
(1) cctIA 0.35 0.36 0.80
(2) ctcIP 0.19 0.18 0.88
(3) cctVA 0.18 0.16 0.15
(4) actIA 0.13 0.13 0.49
(5) ctcVP 0.06 0.08 0.07
(6) cccIP 0.07 0.07 0.50
(7) cctIP 0.02 0.01 0.93
aPolymorphisms in 5' to 3' order as indicated in Table 1. bGlobal score statistic = 6.91, df = 7, P = 0.44
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predisposition, we constructed multilocus haplotypes and
observed similar frequencies in cases and controls. We
found six common haplotypes. Recently, the NIEHS Envi-
ronmental Genome Project at the University of Washington
released resequencing data based on 90 individuals (the
PDR90 population; individual genotypes are available on
line: http://egp.gs.washington.edu/genes.html) and identi-
fied nine common SNPs (frequency ≥ 5%) in ERBB2. All
the common haplotypes (frequency ≥ 5%) were tagged by
our set of five SNPs, even though, as expected given the
multiethnicity of PDR90, differences in frequencies were
seen between the two populations (data not shown). Craw-
ford and colleagues resequenced 100 candidate genes
involved in inflammation, lipid metabolism, and blood pres-
sure regulation and showed that in a population of Euro-
pean descent the average number of common haplotypes
per gene was 4.5, with a maximum number of 8 observed
in only two genes [25]. We are therefore confident that we
have detected all common ERBB2 haplotypes present in
our population. We limited our study to common polymor-
phisms. A larger study set would be needed to identify a
rarer polymorphism involved in disease predisposition. For
example, dominant alleles with a frequency of 2% would
require more than 4000 cases and 4000 controls to detect
a relative risk of 1.5 significant at the 1% level with 90%
power. We cannot exclude the possibility that a common
SNP might have a differential effect in another ethnic group
via gene–gene or gene–environment interactions, or that a
predisposing SNP might be present exclusively in another
population [26]. In summary, we conducted a large case–
control study of ERBB2 and breast cancer. We genotyped
five common SNPs, including the much-studied I655V pol-
ymorphism, and saw no association with the disease. Our
set of SNPs generated all common haplotypes, and no dif-
ferences in haplotype frequencies were seen between
cases and controls.
Conclusion
In our population, common ERBB2 polymorphisms are not
involved in predisposition to breast cancer.
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